Skip to main content
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. — Investor Relations & Filings

Ticker · INKT ISIN · US6036931029 LEI · 529900Z7778N8ZY89B90 US Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US INKT

About MiNK Therapeutics, Inc.

https://www.minktherapeutics.com

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. The company's platform harnesses the dual properties of iNKT cells, which combine the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells to enhance both innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy administered without requiring lymphodepletion or HLA matching. It is currently in clinical trials for solid tumors, severe acute respiratory distress syndrome (ARDS), and Graft versus Host Disease (GvHD). MiNK is also developing a next-generation technology platform for engineered iNKT cells and bispecific iNKT cell engagers for precision targeting.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K
Earnings Release Classification · 90% confidence The document is a U.S. SEC Form 8-K current report filed under Item 2.02 (“Results of Operations and Financial Condition”) that furnishes a press release announcing the company’s quarterly financial results for the period ended March 31, 2026. This is the initial announcement of periodical financial results (key highlights only), matching the definition of an Earnings Release. Q1 2026
2026-05-15 English
10-K - MiNK Therapeutics, Inc. (0001840229) (Filer)
Annual Report FY 2025
2026-03-31 English
8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2026, reporting the company's financial results for the quarter and year ended December 31, 2025. It references a press release (Exhibit 99.1) announcing these results. The text explicitly states that the information is being furnished and is not "filed" for purposes of Section 18, indicating this is an earnings release type of announcement rather than a full financial report. The document length is 3402 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly or annual report. Therefore, the document is best classified as an Earnings Release (ER).
2026-03-31 English
8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content discusses ongoing discussions about potential combination trials and strategic minority investments but does not disclose any binding agreements or detailed financial data. The document is relatively short (3802 characters) and serves as an announcement of events rather than a detailed financial or management report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature of Form 8-K filings and the content, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-27 English
8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 13, 2026, for MiNK Therapeutics, Inc. The content focuses on the appointment of new principal financial and accounting officers, detailing their backgrounds and roles. There is no financial data, earnings information, or report publication mentioned. The primary subject is changes in senior management positions. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 6622 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report types. Therefore, the correct classification is MANG with high confidence.
2026-03-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.